NCT04710576招募中2 期
AGAVE-201, A Phase 2, Open-label, Randomized, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of Axatilimab at 3 Different Doses in Patients With Recurrent or Refractory Active Chronic Graft Versus Host Disease Who Have Received at Least 2 Lines of Systemic Therapy
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 296
- 试验地点
- 230
- 主要终点
- Overall Response Rate (ORR) in the First 6 Cycles as Defined by the 2014 NIH Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-Versus-Host Disease (cGVHD)
研究概览
简要总结
This is a Phase 2 study to evaluate the efficacy, safety, and tolerability of axatilimab at 3 different dose levels in participants with recurrent or refractory active chronic graft versus host disease (cGVHD) who have received at least 2 prior lines of systemic therapy.
详细描述
AGAVE-201 is a Phase 2, open-label, randomized, multicenter study to evaluate the efficacy, safety, and tolerability of axatilimab in participants with recurrent or refractory active cGVHD after failure of at least 2 prior lines of systemic therapy due to progression of disease, intolerability, or toxicity.
Participants will be randomized to receive 1 of 3 different axatilimab treatment regimens in 28-day treatment cycles for up to 2 years.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 2 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participants must be 2 years of age or older, at the time of signing the informed consent.
- •Participants who are allogeneic hematopoietic stem cell transplantation (HSCT) recipients with active cGVHD requiring systemic immune suppression. Active cGVHD is defined as the presence of signs and symptoms of cGVHD per 2014 NIH Consensus Development Project on Criteria for Clinical trials in cGVHD.
- •Participants with refractory or recurrent active cGVHD despite at least 2 lines of systemic therapy.
- •Refractory disease defined as meeting any of the following criteria:
- •The development of 1 or more new sites of disease while being treated for cGVHD.
- •Progression of existing sites of disease despite at least 1 month of standard or investigation therapy for cGVHD.
- •Participants who have not achieved a response within 3 months on their prior therapy for cGVHD and for whom the treating physician believes a new systemic therapy is required.
- •Recurrent cGVHD is active, symptomatic disease (after an initial response to prior therapy) as defined, based on the NIH 2014 consensus criteria, by organ-specific or global assessment or for which the physician believes that a new line of systemic therapy is required.
- •Participants may have persistent, active acute and cGVHD manifestations (overlap syndrome), as defined by 2014 NIH Consensus Development Project on Criteria for Clinical trials in cGVHD.
- •Karnofsky Performance Scale of ≥60 (if aged 16 years or older); Lansky Performance Score of ≥60 (if aged <16 years)
- •Adequate organ and bone marrow functions evaluated during the 14 days prior to randomization.
- •Creatinine clearance (CrCl) ≥30 milliliter/minute based on the Cockcroft-Gault formula in adult participants and Schwartz formula in pediatric participants.
- •Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
- •Concomitant use a of systemic corticosteroid is allowed but not required. Topical and inhaled corticosteroid agents are allowed. If a participant is taking corticosteroids at study randomization, they must be on a stable dose of corticosteroids for at least 2 weeks prior to Cycle 1 Day
- •Concomitant use of CNI or mammalian target of repamycin (mTOR) inhibitors (sirolimus or everolimus) is allowed but not required.
- •Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and protocol. A parent/guardian should provide consent for pediatric participants unable to provide consent themselves; in addition, where applicable pediatric participants should sign their own assent form.
排除标准
- •Participants are excluded from the study if any of the following criteria apply:
- •Has acute GVHD without manifestations of cGVHD.
- •Any evidence (histologic, cytogenetic, molecular, hematologic, or mixed) of relapse of the underlying cancer or post-transplant lymphoproliferative disease at the time of screening.
- •History of acute or chronic pancreatitis.
- •History of myositis.
- •History or other evidence of severe illness, uncontrolled infection or any other conditions that would make the participant, in the opinion of the Investigator, unsuitable for the study.
- •Participants with acquired immune deficiency syndrome (AIDS).
- •Hepatitis B (defined as hepatitis B virus [HBV] surface antigen positive and HBV core antibody positive, with positive HBV deoxyribonucleic acid [DNA], or HBV positive core antibody alone with positive HBV DNA. Hepatitis C (defined as positive hepatitis C [HCV] antibody with positive HCV ribonucleic acid [RNA]).
- •Diagnosed with another malignancy (other than malignancy for which transplant was performed) within 3 years of randomization, unless previously treated with curative intent and approved by Sponsor's Medical Monitor (for example, completely resected basal cell or squamous cell carcinoma of the skin, resected in situ cervical malignancy, resected breast ductal carcinoma in situ, or low-risk prostate cancer after curative resection).
- •Female participant who is pregnant or breastfeeding.
- •Previous exposure to CSF1-R targeted therapies.
- •Taking agents for treatment of cGVHD other than corticosteroids or either a CNI or mTOR inhibitor is prohibited.
- •For approved or commonly used agents, other than corticosteroids, CNI and mTOR inhibitor, a washout of 2 weeks or 5 half-lives, whichever is shorter, is required at study enrollment.
- •Receiving another investigational treatment within 28 days of randomization.
- •Participants should not be participating in any other interventional study. Pediatric participants are encouraged to also participate in the ongoing developmental studies of the Pediatric cGVHD Symptom Scale (PCSS).
研究组 & 干预措施
Axatilimab Dose Cohort 1
Experimental
Participants will be administered axatilimab 0.3 milligrams (mg)/kilogram (kg) intravenously (IV) every 2 weeks for up to 2 years.
干预措施: Axatilimab (Drug)
Axatilimab Dose Cohort 2
Experimental
Participants will be administered axatilimab 1 mg/kg IV every 2 weeks for up to 2 years.
干预措施: Axatilimab (Drug)
Axatilimab Dose Cohort 3
Experimental
Participants will be administered axatilimab 3 mg/kg IV every 4 weeks for up to 2 years.
干预措施: Axatilimab (Drug)
结局指标
主要结局
Overall Response Rate (ORR) in the First 6 Cycles as Defined by the 2014 NIH Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-Versus-Host Disease (cGVHD)
时间窗: First 6 cycles (up to Cycle 7 Day 1; each cycle = 4 weeks)
The ORR was defined as the percentage of participants with objective response (complete response \[CR\] or partial response \[PR\]). CR was defined as resolution of all manifestations in each organ or site, and PR was defined as improvement in at least 1 organ or site without progression in any other organ or site.
次要结局
- ORR on Study as Defined by the 2014 NIH Consensus Development Project on Criteria for Clinical Trials in cGVHD(Up to 2 years)
- Number of Participants With a Clinically Significant Improvement in Normalized Score on the Modified Lee Symptom Scale(Up to 2 years)
- Duration of Response(Up to 2 years)
- Sustained Response Rate(Up to 2 years)
- Organ-specific Response Rate(Up to 2 years)
- Joints and Fascia Response Rate Based on Refined NIH Response Algorithm for cGVHD(Up to 2 years)
- Percent Reductions in Average Daily Doses (or Equivalent) of Corticosteroid(Up to 2 years)
- Number of Participants Who Discontinue Corticosteroid Use(Up to 2 years)
- Percent Reductions in Average Daily Doses (or Equivalent) of Calcineurin Inhibitors (CNI)(Up to 2 years)
- Number of Participants Who Discontinue CNIs(Up to 2 years)
- Change From Baseline in Circulating Monocyte Number and Phenotype (CD14/16)(Baseline, up to 2 years)
- Number of Participants With Anti-Drug Antibody(Up to 2 years)
- Area Under the Plasma Concentration-time Curve (AUC) From Time 0 to Time of Last Measurable Concentration (AUC0-t)(Approximately 12 months)
- Number of Participants With Treatment-emergent Adverse Events(Up to 2 years)
- Change From Baseline in Bone Turnover Markers(Baseline, up to 2 years)
- Change From Baseline in Bone Density(Baseline, up to 2 years)
- Change From Baseline in Colony Stimulating Factor 1 (CSF-1) and Interleukin 34 (IL-34) Levels(Baseline, up to 2 years)
研究者
研究点 (230)
Loading locations...
相似试验
进行中（未招募）
2 期
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host DiseaseChronic Graft-versus-host-diseaseNCT06388564Incyte Corporation130
招募中
1 期
Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast CancerPALB2-Mutated Breast CarcinomaHER2-negative Breast CancerBRCA1 MutationBRCA2 MutationBreast CancerNCT06488378Dana-Farber Cancer Institute20
招募中
3 期
A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host DiseaseChronic Graft-versus-host-diseaseNCT06585774Incyte Corporation240
招募中
1 期
Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid TumorsAdvanced Malignant Solid NeoplasmMetastatic Malignant Solid NeoplasmRecurrent Malignant Solid NeoplasmRefractory Malignant Solid NeoplasmNCT06320405OHSU Knight Cancer Institute38
已完成
1 期
A Phase 1/2 Study to Evaluate Axatilimab in Participants With Active cGVHDChronic Graft-versus-host-diseaseNCT03604692Syndax Pharmaceuticals41